While impressive progress has been made in the clinical application of immunomodulatory agents, there are still some problems, such as CD33 and CD123 also expressed in normal hematopoietic cells, some AML patients not sensitive to anti-PD-1/PD-L1 [17]. Here, CD274 is linked to acute myeloid leukemia.